Eradivir's goal is to focus the power of the immune system to treat disease. Its small-molecule, bispecific immunotherapy tethers a patient's immune cells specifically to a diseased cell facilitating its rapid and selective destruction. Its first drug to go into humans, EV25, is directed against influenza.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/25/24 | $10,250,000 | Series A |
Philip Low | undisclosed |
